RT Journal Article
SR Electronic
T1 Analytical Validation of a Pan-Cancer NGS Assay for In-House Liquid Biopsy Testing: An International Multicenter Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.17.24313324
DO 10.1101/2024.10.17.24313324
A1 Lescuyer, Gaëlle
A1 Harlé, Alexandre
A1 Kumar, Hari Shankar
A1 Constantoulakis, Pantelis
A1 Pfarr, Nicole
A1 Heitzer, Ellen
A1 Michon, Clémence
A1 Russo, Gianluca
A1 Speel, Ernst-Jan M
A1 Piecyk, Marie
A1 Husson, Marie
A1 Christopoulou, Georgia
A1 Mayr, Eva-Maria
A1 Koppermann, Mai-Lan
A1 Passot, Christophe
A1 Graf, Ricarda
A1 Aoul, Anes Hadjadj
A1 Bourdon, Violaine
A1 Dubbink, Hendrikus J
A1 van Marion, Ronald
A1 Demers, Imke
A1 Dingemans, Anne-Marie C
A1 Troncone, Giancarlo
A1 Pepe, Francesco
A1 Muinelo-Romay, Laura
A1 Díaz-Lagares, Ángel
A1 Rodriguez-Casanova, Aitor
A1 Lago Lestón, Ramón Manuel
A1 Pathak, Deepak
A1 Shah, Parth
A1 Parillaud, Romain V
A1 Martínez de Ilarduya, Oskar
A1 Behr, Jonas
A1 Rapin, Alexis
A1 Vetterli, Thomas
A1 Boppudi, Sanga Mitra
A1 Malapelle, Umberto
A1 Payen-Gay, Lea
YR 2024
UL http://medrxiv.org/content/early/2024/10/25/2024.10.17.24313324.abstract
AB Background Liquid biopsy (LBx) assays are transforming precision oncology by the screening of genomic alterations in cfDNA. These assays provide a less invasive alternative to tissue biopsies, which are not always feasible. Molecular pathology laboratories require LBx assays that detect variants at low allele frequencies using standardized methods.Methods This study evaluated the Hedera Profiling 2 ctDNA test panel (HP2) (Hedera Dx, Epalinges, Switzerland), a hybrid capture-based NGS assay for the detection of somatic alterations from cfDNA. Covering 32 genes, HP2 enables the detection of SNVs, Indels, Fusions, CNVs, and MSI status from a single DNA-only workflow. The analytical performance was assessed using reference standards and a diverse cohort of 137 clinical samples pre-characterized by orthogonal methods.Results In reference standards at 0.5% VAF, detection sensitivity and specificity for SNVs/Indels were 96.92% and 99.67%, respectively, and 100% each for Fusions. For MSI with VAFs of ≥1% and CNVs with VAFs of ≥ 2% both achieved 100% sensitivity.Conclusion This international, multicenter analytical performance evaluation study across a large number of hospital laboratories demonstrated high concordance of HP2 assay with orthogonal methods, confirming its significant potential as a highly sensitive, and efficient Pan-Cancer test for future decentralized LBx testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:On behalf of the Scientific and Ethics Committee, after careful examination, I formally confirm that none ethical approval was required for the paper entitled "Validation of a Pan-Cancer NGS Liquid Biopsy Test for Routine Hospital Use: An International Multicenter Clinical Performance Evaluation". — Pr Cyrille CONFAVREUX (President of the Comité Scientifique et Éthique des Hospices Civils de LYON CSE-HCL — IRB 00013204)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript